Cargando…

Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”

Detalles Bibliográficos
Autores principales:	Hopkins, Ashley M., Kichenadasse, Ganessan, Abuhelwa, Ahmad Y., McKinnon, Ross A., Rowland, Andrew, Sorich, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Reply
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345086/ https://www.ncbi.nlm.nih.gov/pubmed/34359664 http://dx.doi.org/10.3390/cancers13153763

Ejemplares similares

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
por: Auclin, Edouard, et al.
Publicado: (2021)

Reply to Kielb et al. Untapped Potential for Female Patients? Comment on “Lucà et al. Update on Management of Cardiovascular Diseases in Women. J. Clin. Med. 2022, 11, 1176”
por: Lucà, Fabiana, et al.
Publicado: (2022)

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

Reply to De Luca et al. Comment on “Marra et al. Metastatic Renal Cell Carcinoma to the Soft Tissue 27 Years after Radical Nephrectomy: A Case Report. Medicina 2023, 59, 150”
por: Alfano, Carmine, et al.
Publicado: (2023)

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials
por: Socinski, Mark A., et al.
Publicado: (2023)

Response to Letter to Editor by Dr. Aminnejad et al.
por: Shahrokhirad, Reyhaneh, et al.
Publicado: (2019)

Response to: gender differences on neuromuscular strategy during drop jump: a comment on Helm et al. (2019) by Di Giminiani et al.
por: Helm, M., et al.
Publicado: (2020)

Reply to De Giorgi et al. Comment on “Kesić et al. Early Diagnostics of Vulvar Intraepithelial Neoplasia. Cancers 2022, 14, 1822”
por: Kesić, Vesna, et al.
Publicado: (2022)

Reply to Krupenko et al., Comment on “Lee et al. The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer Cancers 2020, 12, 1382”
por: Lee, Seon-Hyeong, et al.
Publicado: (2021)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Reply to Aguenaou et al. Comment on “Muzzioli et al. Are Front-of-Pack Labels a Health Policy Tool? Nutrients 2022, 14, 771”
por: Muzzioli, Luca, et al.
Publicado: (2022)

Reply to Vrijdag et al. Comment on “Mankowska et al. Critical Flicker Fusion Frequency: A Narrative Review. Medicina 2021, 57, 1096”
por: Mankowska, Natalia D., et al.
Publicado: (2022)

Response to Polosa et al. Comments on Scheffler et al. Cytotoxic Evaluation of E-Liquid Aerosol Using Different Lung Derived Cell Models. Int. J. Environ. Res. Public Health, 2015, 12, 12466-12474
por: Scheffler, Stefanie, et al.
Publicado: (2016)

Reply to Bracke et al. Comment on “Prayag et al. Light Modulation of Human Clocks, Wake, and Sleep. Clocks&Sleep 2019, 1, 193–208”
por: Prayag, Abhishek S., et al.
Publicado: (2021)

Reply to van der Pluijm et al. Comment on “Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. J. Clin. Med. 2022, 11, 781”
por: Calfon-Peretz, Ortal, et al.
Publicado: (2022)

Reply to Zarguan et al. Comment on “Budryn et al. Hydroxybenzoic Acids as Acetylcholinesterase Inhibitors: Calorimetric and Docking Simulation Studies. Nutrients 2022, 14, 2476”
por: Grzelczyk, Joanna, et al.
Publicado: (2022)

Reply to Lissing et al. Comment on “Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. Cancers 2022, 14, 2947”
por: Ramai, Daryl, et al.
Publicado: (2023)

Reply to Nagano et al
por: Hammarström, Helena, et al.
Publicado: (2022)

Reply to Thornhill et al
por: Vähäsarja, Niko, et al.
Publicado: (2022)

Response to Comments by Vuksan V. et al., Nutrients 2017, 9, 398, Regarding an Article by Solah V.A. et al., Nutrients 2017, 9, 149
por: Solah, Vicky A., et al.
Publicado: (2017)

Reply to Chaudhuri et al. Comment on “Balwierz et al. Potential Carcinogens in Makeup Cosmetics. Int. J. Environ. Res. Public Health 2023, 20, 4780”
por: Balwierz, Radosław, et al.
Publicado: (2023)

Reply to Taylor et al. Comment on “Manna et al. SARS-CoV-2 Inactivation in Aerosol by Means of Radiated Microwaves. Viruses 2023, 15, 1443”
por: Manna, Antonio, et al.
Publicado: (2023)

Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
por: Remon, Jordi, et al.
Publicado: (2020)

Revision of J3Gen Validity of the Attacks by Peinado et al.
por: Peinado, Alberto, et al.
Publicado: (2015)

Response to the Article on Antibiotics and Immune Checkpoint Inhibitors by Lin et al.
por: Cheung, Ka Shing, et al.
Publicado: (2022)

Response to Comment on Jaworska, J. et al. Consensus on the Application of Lung Ultrasound in Pneumonia and Bronchiolitis in Children. Diagnostics 2020, 10, 935
por: Komorowska-Piotrowska, Anna, et al.
Publicado: (2021)

Reply to Dhawan et al. Comment on “Kim et al. The Association between Coffee Consumption and Risk of Colorectal Cancer in a Korean Population. Nutrients 2021, 13, 2753”
por: Kim, Youngyo, et al.
Publicado: (2021)

Reply to Campbell et al. Comment on “Hogas et al. Salt, Not Always a Cardiovascular Enemy? A Mini-Review and Modern Perspective. Medicina 2022, 58, 1175”
por: Hogas, Mihai, et al.
Publicado: (2022)

Reply to Abenavoli et al. Comment on “Clayton-Chubb et al. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023, 15, 687”
por: Clayton-Chubb, Daniel, et al.
Publicado: (2023)

Reply to Mankowska et al. Comment on “Muth et al. Assessing Critical Flicker Fusion Frequency: Which Confounders? A Narrative Review. Medicina 2023, 59, 800”
por: Muth, Thomas, et al.
Publicado: (2023)

Reply to Twycross et al. Comment on “Ramos-Rincon et al. Palliative Sedation in COVID-19 End-of-Life Care. Retrospective Cohort Study. Medicina 2021, 57, 873”
por: Ramos-Rincon, Jose-Manuel, et al.
Publicado: (2022)

Reply to Witthöft et al. Comment on “Wardzinski et al. Mobile Phone Radiation Deflects Brain Energy Homeostasis and Prompts Human Food Ingestion. Nutrients 2022, 14, 339”
por: Wardzinski, Ewelina K., et al.
Publicado: (2022)

Reply to Alt et al. Comment on “Lunz et al. Impact and Modification of the New PJI-TNM Classification for Periprosthetic Joint Infections. J. Clin. Med. 2023, 12, 1262”
por: Lunz, Andre, et al.
Publicado: (2023)

Reply to Comment by Young et al.
por: Mathews, F., et al.
Publicado: (2009)

Reply to Mirabelli et al. Is Mesothelioma Unrelated to the Lung Asbestos Burden? Comment on “Visonà et al. Inorganic Fiber Lung Burden in Subjects with Occupational and/or Anthropogenic Environmental Asbestos Exposure in Broni (Pavia, Northern Italy): An SEM-EDS Study on Autoptic Samples. Int. J. Environ. Res. Public Health 2021, 18, 2053”
por: Visonà, Silvia Damiana, et al.
Publicado: (2021)

Hering Hermeneutics: Supplement to Translation and Commentary of Hering (1899) by Strasburger et al.
por: Westheimer, Gerald
Publicado: (2018)

Reply to Neupane et al.: Replication study of AD‐associated rare variants
por: Prokopenko, Dmitry, et al.
Publicado: (2022)

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Reply to Shaikh et al. Comment on “Rochmah et al. Economic Burden of Stroke Disease: A Systematic Review. Int. J. Environ. Res. Public Health 2021, 18, 7552”
por: Rochmah, Thinni Nurul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a71lh35qjgkfprh7ncg5va9ve8